April 14, 2020/COVID-19

Positive Airway Pressure Therapy and COVID-19: What Patients Need to Know

Tell PAP device users to assume increased risk of droplet and aerosolized transmission

20-NEU-1880306-PAP-therapy-650×450

All forms of positive airway pressure (PAP) therapy should be assumed to increase the risk of droplet and aerosolized transmission of COVID-19.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

So advises a practical review of PAP therapy and COVID-19 transmission published by Cleveland Clinic sleep disorders specialist Colleen G. Lance, MD, in a collection of COVID-19 Curbside Consults from Cleveland Clinic Journal of Medicine.

Noting that PAP therapy is an open system that can generate contact, droplet and airborne pathogens, Dr. Lance outlines evidence supporting implementation of contact, droplet and airborne precautions for patients on PAP therapy in the context of the COVID-19 pandemic.

Dr. Lance helpfully summarizes recommendations on PAP therapy and COVID-19 from the American Academy of Sleep Medicine (AASM) relating to two broad patient scenarios:

Advertisement
  • PAP use at home among asymptomatic individuals. Highlights include advice that the PAP therapy user should sleep in a separate bedroom and, if possible, use a separate bathroom.
  • PAP use among individuals with suspected or confirmed COVID-19. The key guidance here is that discontinuation of PAP therapy for a short period may be reasonable until the patient is no longer contagious. In cases of temporary discontinuation, interim measures for reducing sleep apnea should be considered, including positional therapy during sleep, use of a dental appliance (if the patient has one), treatment of nasal congestion, and avoiding alcohol and sedating medications.

The review also distills recommendations from an AASM guidance on sleep clinic and sleep laboratory activities during substantial community spread of COVID-19. Central advice here is that in-laboratory sleep studies should be postponed for all patients and home sleep apnea testing should be postponed unless disposable testing devices are used exclusively.

Dr. Lance shares that current practice of Cleveland Clinic’s Sleep Disorders Center is to evaluate potentially urgent requests for in-lab sleep studies on a case-by-case basis. Additionally, Cleveland Clinic uses disposable devices for home sleep apnea testing and disinfects all nondisposable components.

The review concludes with an overview of evidence on emergency use of PAP equipment as a substitute for ventilation, noting that basic continuous PAP and bilevel PAP devices are not designed to function as ventilators and that additional PAP devices, including those with noninvasive ventilation capacity, are not substitutes for ventilators in the context of acute respiratory failure.

Advertisement

Dr. Lance’s referenced review article from Cleveland Clinic Journal of Medicine’s COVID-19 Curbside Consults is available here.

Related Articles

Stellate Ganglion Block
May 17, 2023/COVID-19
Nerve Block Shows Promise for Long COVID-Related Olfactory or Gustatory Dysfunction

Patients report improved sense of smell and taste

Covid image
April 26, 2023/COVID-19
What Long COVID Means for Rheumatologists (Video)

Clinicians who are accustomed to uncertainty can do well by patients

Covid related skin effects
April 4, 2023/COVID-19
Cutaneous Manifestations of COVID-19 in Special Populations

Unique skin changes can occur after infection or vaccine

Glucometer
February 10, 2023/COVID-19
Effects of COVID-19 on Blood Sugar and Type 2 Diabetes

Cleveland Clinic analysis suggests that obtaining care for the virus might reveal a previously undiagnosed condition

covid-19
January 13, 2023/COVID-19
Optimal Management of High Risk Immunocompromised Patients in the COVID-19 Era

As the pandemic evolves, rheumatologists must continue to be mindful of most vulnerable patients

covid-19 virus
January 12, 2023/COVID-19
Real World Experience with Tixagevimab/Cilgavimab in B-Cell-Depleted Patients

Early results suggest positive outcomes from COVID-19 PrEP treatment

Eosinophilic Fasciitis
November 29, 2022/COVID-19
New Onset Eosinophilic Fasciitis after COVID-19 Infection

Could the virus have caused the condition or triggered previously undiagnosed disease?

COVID-19 and rash
June 16, 2022/COVID-19
Common Skin Signs of COVID-19 in Adults: An Update

Five categories of cutaneous abnormalities are associated with COVID-19

Ad